BMS202 (PD-1/PD-L1 inhibitor 2) - Moligand™, 10mM in DMSO , Agonist of CB 1 receptor;Agonist of CB 2 receptor, CAS No.1675203-84-5, Agonist of CB 1 receptor;Agonist of CB 2 receptor

CAS: 1675203-84-5 Cat. No.: B408242 Peso molecular: 419.5

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

N-[2-[[[2-methoxy-6-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]-3-pyridinyl]methyl]amino]ethyl]-acetamide

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Descripción general

Information

BMS202 (PD-1/PD-L1 inhibitor 2) BMS202 (PD-1/PD-L1 inhibitor 2) is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.
In vitro

In vivo

Cell Data

cell lines：LNCaP, 22Rv1, DU145, and PC3

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Sinónimos

N-[2-[[[2-methoxy-6-[(2-methyl[1, 1'-biphenyl]-3-yl)methoxy]-3-pyridinyl]methyl]amino]ethyl]-acetamide

Especificaciones y pureza

Moligand™, 10mM in DMSO

Mecanismos bioquímicos y fisiológicos

BMS202 (PD-1/PD-L1 inhibitor 2) is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.

Condiciones de almacenamiento de almacenamiento

Store at -80°C

Enviado en

Dry ice packs + Cold packs

Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.

Grado

Moligand™

Tipo de acción

AGONIST

Mecanismo de acción

Agonist of CB 1 receptor;Agonist of CB 2 receptor

Nombres e identificadores

• Isómeros SMILES: CC1=C(C=CC=C1C2=CC=CC=C2)COC3=NC(=C(C=C3)CNCCNC(=O)C)OC
• CAS alternativo: 1675203-84-5
• Términos de entrada MeSH: BMS202;N-(2-((2-Methoxy-6-(2-methyl-biphenyl-3-ylmethoxy)-pyridin-3-ylmethyl)-amino)-ethyl)-acetamide;PCC0208025
• Peso molecular: 419.5
• Reaxy-Rn: 27956188
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=27956188&ln=

Objetivos asociados (humanos)

CNR1 Tclin Cannabinoid receptor 1 (1 Activities)

Discover Target: CNR1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CNR2 Tchem Cannabinoid receptor 2 (1 Activities)

Discover Target: CNR2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CD274 Tclin Programmed cell death 1 ligand 1 (0 Activities)

Discover Target: CD274

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Referencias

1. Yiqiang OuYang, Jian Gao, Lei Zhao, Junfeng Lu, Haiqing Zhong, Hua Tang, Shuanglong Jin, Lu Yue, Yuezhen Li, Wenjie Guo, Qiang Xu, Yisheng Lai.  (2021)  Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo.  JOURNAL OF MEDICINAL CHEMISTRY,      [PMID:34037385] [10.1021/acs.jmedchem.1c00370]

2. Ruoxia Wu, Jiaqing Xiong, Ting Zhou, Zhen Zhang, Zhen Huang, Sha Tian, Yongli Wang.  (2023)  Quercetin/Anti-PD-1 Antibody Combination Therapy Regulates the Gut Microbiota, Impacts Macrophage Immunity and Reshapes the Hepatocellular Carcinoma Tumor Microenvironment.  Frontiers in Bioscience-Landmark,  28  (12): (327).  [PMID:38179731] [10.31083/j.fbl2812327]

3. Qiuyang Huang, Xiaoling Zang, Zhiwei Zhang, Hang Yu, Baoyan Ding, Zhuangzhuang Li, Simin Cheng, Xin Zhang, Mustafa R.K. Ali, Xue Qiu, Zhihua Lv.  (2023)  Study on endogenous inhibitors against PD-L1: cAMP as a potential candidate.  INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,      [PMID:36646351] [10.1016/j.ijbiomac.2023.123266]

4. Sha Liu, Lina Wang, Yupeng Wang, Lina Geng.  (2025)  ROS-responsive multifunctional DCS-based micelle-hydrogel for simultaneously inhibiting post-melanoma-resection recurrence and promoting wound healing.  Nanoscale,      [PMID:41568423] [10.1039/D5NR03938J]